Salehi Najmeh, Amiri-Yekta Amir, Totonchi Mehdi
Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Cell J. 2020 Jul;22(Suppl 1):148-150. doi: 10.22074/cellj.2020.7524. Epub 2020 Jul 18.
The etiologic agent SARS-CoV-2 has caused the outbreak of COVID-19 which is spread widely around the world. It is vital to uncover and investigate the full genome sequence of SARS-CoV-2 throughout the world to track changes in this virus. To this purpose, SARS-CoV-2 full genome sequence profiling of 20 patients in Iran and different countries that already had a travel history to Iran or contacts with Iranian cases were provided from the GISAID database. The bioinformatics analysis showed 44 different nucleotide mutations that caused 26 nonsynonymous mutations in protein sequences with regard to the reference full genome of the SARS-CoV-2 sequence (NC_045512.2). R207C, V378I, M2796I, L3606F, and A6407V in ORF1ab were common mutations in these sequences. Also, some of the detected mutations only were found in Iranian data in comparison with all the available sequences of SARS-CoV-2. The position of S protein mutations showed they were far from the binding site of this protein with angiotensin-converting enzyme-2 (ACE2) as the host cell receptor. These results can be helpful to design specific diagnostic tests, trace the SARS-CoV-2 sequence changes in Iran, and explore therapeutic drugs and vaccines.
病原体严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了2019冠状病毒病(COVID-19)的全球大流行。全面揭示和研究SARS-CoV-2的全基因组序列对于追踪该病毒的变化至关重要。为此,从全球共享流感数据倡议组织(GISAID)数据库中获取了20名伊朗患者以及有伊朗旅行史或与伊朗病例有接触的其他国家患者的SARS-CoV-2全基因组序列分析结果。生物信息学分析显示,与SARS-CoV-2序列的参考全基因组(NC_045512.2)相比,有44个不同的核苷酸突变导致蛋白质序列中出现26个非同义突变。开放阅读框1ab(ORF1ab)中的R207C、V378I、M2796I、L3606F和A6407V是这些序列中的常见突变。此外,与所有可用的SARS-CoV-2序列相比,一些检测到的突变仅在伊朗的数据中发现。刺突蛋白(S蛋白)突变的位置表明,它们距离该蛋白与作为宿主细胞受体的血管紧张素转换酶2(ACE2)的结合位点较远。这些结果有助于设计特异性诊断测试、追踪伊朗SARS-CoV-2序列的变化以及探索治疗药物和疫苗。